tbuckley/cabot-search huggingface dataset:
From the National Institutes of Health
Authors: James B. Wyngaarden
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multifunctional liquid metal-based nanoparticles with glycolysis and mitochondrial metabolism inhibition for tumor photothermal therapy
Authors: Xing-Lan Ding, Miao-Deng Liu, Qian Cheng, Wen-Hui Guo, Mei-Ting Niu, Qian-Xiao Huang, Xuan Zeng, Xian-Zheng Zhang
Journal: Biomaterials (2022)
Homologous recombination deficiency testing in first-line ovarian cancer
Authors: K.N. Moore, A. du Bois
Journal: Annals of Oncology (2022)

In this issue of Annals of Oncology, Vergote and colleagues1 have published a comprehensive set of experts’ consensus statements based on literature review and clinical practice on five critical topics regarding the type and location of molecular testing included in the care of women with ovarian cancer:
Physician Need
Authors: Robert Mulhausen
Journal: JAMA (1989)

To model a base level of physician demand in a managed health care system, we examined in 1983 the ratios by specialty of full-time equivalent physicians to health maintenance organization members in seven large, closed-panel health maintenance organizations, each with more than 100 000 members. The medical director of each plan was surveyed by mailed questionnaire and telephone interview to determine the plan's number of full-time equivalent physicians by specialty and members served. Out-of-plan physicians contracted by the group were included within the specialty distribution wherever possible. We compared our findings (4779.4 full-time equivalent physicians serving 4 297 790 members) with Graduate Medical Education National Advisory Committee and others' projections of physician need and supply. Based on this model and unknowns that might affect utilization, our study suggests that at least 111 physicians per 100 000 population would be necessary in a system that emphasized reduced utilization of services and that more primary care physicians would be needed than the Graduate Medical Education National Advisory Committee predicted would be available. (<i>JAMA</i>. 1989;261:1930-1934)
Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis
Authors: Claudius Speer, Maximilian Töllner, Louise Benning, Katrin Klein, Marie Bartenschlager, Christian Nusshag, Florian Kälble, Paula Reichel, Paul Schnitzler, Martin Zeier, Christian Morath, Wilhelm H Schmitt, Raoul Bergner, Ralf Bartenschlager, Matthias Schaier
Journal: Annals of the Rheumatic Diseases (2022)
International Comments
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression of matrix metalloproteinase-2 (MMP 2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP 2) in vivo during myocardial ischemic injury and in vitro in cardiac-derived fibroblasts and endothelial cells Dolores Cortez, James Colston, Teresa Frosto, Bysani Chandrasekar, Gregory Freeman. Univ. of Texas Health Science Center at San Antonio, San Antonio, TX
Journal: Journal of the American College of Cardiology (2001)
Leads from the MMWR. Reye's syndrome--United States, 1985
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessing reproducibility of inherited variants detected with short-read whole genome sequencing
Authors: Bohu Pan, Luyao Ren, Vitor Onuchic, Meijian Guan, Rebecca Kusko, Steve Bruinsma, Len Trigg, Andreas Scherer, Baitang Ning, Chaoyang Zhang, Christine Glidewell-Kenney, Chunlin Xiao, Eric Donaldson, Fritz J. Sedlazeck, Gary Schroth, Gokhan Yavas, Haiying Grunenwald, Haodong Chen, Heather Meinholz, Joe Meehan, Jing Wang, Jingcheng Yang, Jonathan Foox, Jun Shang, Kelci Miclaus, Lianhua Dong, Leming Shi, Marghoob Mohiyuddin, Mehdi Pirooznia, Ping Gong, Rooz Golshani, Russ Wolfinger, Samir Lababidi, Sayed Mohammad Ebrahim Sahraeian, Steve Sherry, Tao Han, Tao Chen, Tieliu Shi, Wanwan Hou, Weigong Ge, Wen Zou, Wenjing Guo, Wenjun Bao, Wenzhong Xiao, Xiaohui Fan, Yoichi Gondo, Ying Yu, Yongmei Zhao, Zhenqiang Su, Zhichao Liu, Weida Tong, Wenming Xiao, Justin M. Zook, Yuanting Zheng, Huixiao Hong
Journal: Genome biology (2022)

Abstract Background Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant call quality. Systematically assessing reproducibility of inherited variants with WGS and impact of each step in the process is needed for understanding and improving quality of inherited variants from WGS. Results To dissect the impact of factors involved in detection of inherited variants with WGS, we sequence triplicates of eight DNA samples representing two populations on three short-read sequencing platforms using three library kits in six labs and call variants with 56 combinations of aligners and callers. We find that bioinformatics pipelines (callers and aligners) have a larger impact on variant reproducibility than WGS platform or library preparation. Single-nucleotide variants (SNVs), particularly outside difficult-to-map regions, are more reproducible than small insertions and deletions (indels), which are least reproducible when &gt; 5 bp. Increasing sequencing coverage improves indel reproducibility but has limited impact on SNVs above 30×. Conclusions Our findings highlight sources of variability in variant detection and the need for improvement of bioinformatics pipelines in the era of precision medicine with WGS.
Viewing education differently: A novel educational approach using virtual tumor board cases.
Authors: John R Ogden, Mohit Shiv Agarwal, Lauren Chiec, Erin Shonkwiler, Michael Chaby, Naomi Dempsey, Michael J. Pishvaian, Samuel J Klempner, Al Bowen Benson, Christopher Hanyoung Lieu, Mohammad Jahanzeb
Journal: Journal of Clinical Oncology (2022)

653 Background: Caring for patients with cancer requires the expertise of specialists from pathology, radiology, surgical, radiation and medical oncology. Cancer centers discuss complicated cases at multidisciplinary tumor boards, where these experts collaborate on the optimal management strategies. Tumor boards present an opportunity for oncology providers to learn current guidelines and manage complex cases. Unfortunately, these opportunities occur infrequently and are limited to individual cancer centers. Virtual tumor board case scenarios could provide a valuable educational resource for professionals in all areas of oncology looking to enhance their knowledge and understanding of complex patient management. Methods: Well-renowned gastrointestinal oncology faculty conducted virtual tumor board panels via an online platform to discuss challenging cases submitted by community oncology providers and trainees. The panel consisted of specialists from radiology, medical, surgical, and radiation oncology. The case discussions were then formatted into individual scenario videos with case-based questions asked at the beginning and end of the discussions. These videos were viewed by trainees and practitioners in various fields of oncology. A survey was conducted to assess the educational value of these videos. Results: 10 unique gastrointestinal scenario videos were created from expert panel case discussions. These were viewed by 12 unique viewers, who were surveyed on their experience. Responders included Fellows/Residents (83%) and advanced practice providers (APPs) (17%). These included trainees/APPs from medical oncology (50%), radiation oncology (42%) and radiology (8%). All 12 responders felt the videos were a valuable educational resource that they would continue to use in the future. Of the responders, 7/12 (58%) felt these virtual scenarios were more educational than their own institutional tumor boards, while the remaining 5/12 (42%) felt they were equally educational. Responders to the survey indicated they would use these videos for a variety of purposes, as indicated below. Conclusions: Scenario videos created from virtual tumor boards conducted by expert panelists can provide a novel and valuable educational resource for trainees across all fields of oncology. It is a convenient way for viewers to stay up to date on current guidelines and apply the knowledge gained to their own practice. Additionally, it allows viewers a unique opportunity to hear from renowned experts in various oncology fields. Expansion and continued production of these scenario videos could enhance the education and practice of professionals in the field of oncology. Further assessment and evaluation of the impacts of these videos will be necessary.[Table: see text]
Abstract 350: The Developmental Origin Of Cardiac Fibroblasts Influences the Efficiency of Direct Reprogramming to Cardiomyocytes
Authors: Sara Ranjbarvaziri, Reza Ardehali
Journal: Circulation Research (2017)

Direct conversion of fibroblasts to cardiomyocytes (CM) is advancing the field of cardiac regeneration. Despite advantages of direct reprogramming, the presence of residual epigenetic memory of the original cells may hinder clinical transition. Thus, choosing a starting cell with similar ontogeny to the desired reprogrammed cell may overcome some of the limitations. Expression of key cardiogenic genes shared between cardiac fibroblasts (CFb) and CM in addition to the abundance of these cells, suggest that CFb may be the optimal autologous cell source for therapeutic manipulation in treating heart disease. We hypothesized that progenitors, transiently expressing Mesp1 generate a sub-population of CFb which are more prone to direct reprogramming and adopt a cardiomyocyte gene profile due to their maintained epigenetic memory. We generated a Mesp1CremTmG mouse to label all cells expressing Mesp1 and their progeny and we observed that the majority of the cells in the heart including CFb are derived from Mesp1 cells. We showed that ~80% of resident CFb are derived from Mesp1 while a minor non-Mesp1 subset also exists. We compared the reprogramming efficiency of CFb of Mesp1 origin to CFb of other origin to induced CM (iCM) by overexpression of specific cardiac transcription factors. Results from immunostaining and gene analysis showed higher expression of cardiac muscle markers in CM induced from Mesp1 CFb. To further delineate potential differences between two subsets, we performed RNAseq and our results showed that the non Mesp1 CFb were enriched in neural crest related genes. We generated Pax3CremTmG mice to lineage trace neural crest-derived cells. Our results confirmed a minor contribution of Pax3 cells to CFb. We developed a modified CLARITY technique to transform the heart into an optically-transparent organ for light-sheet fluorescence imaging. We observed that Pax3 CFb were mainly located in the wall of aorta while Mesp1 CFb were distributed throughout the heart. Additionally, we are studying whether each CFb subset has the tendency to generate a specific subtype of iCM (ventricular, atrial, and nodal CM). These results can identify distinct sub-populations of CFb, which can generate functional cardiomyocytes for cardiac-regenerative therapies.
The Authors Reply:
Authors: Gherardo Finocchiaro, Harshil Dhutia, Andrew D’Silva, Aneil Malhotra, Alexandros Steriotis, Lynne Millar, Keerthi Prakash, Rajay Narain, Michael Papadakis, Rajan Sharma, Sanjay Sharma
Journal: JACC. Cardiovascular imaging (2017)
Reply
Authors: Nazanin Fallah-Rad, Jonathan R. Walker, Anthony Wassef, Matthew Lytwyn, Sheena Bohonis, Tielan Fang, Ganhong Tian, Iain D.C. Kirkpatrick, Pawan K. Singal, Marianne Krahn, Debjani Grenier, Davinder S. Jassal
Journal: Journal of the American College of Cardiology (2011)
The Prognostic value for stroke of a nurse-led screening assessment of 71,527 Scottish middle-aged men I. Ford, A.D. McMahon, J. Pell, C. Packard, P.W. Macfarlane, S.M. Cobbe, J. Shepherd. Robertson Centre for Biostatistics, Glasgow, United Kingdom, Glasgow Royal Infirmary, Glasgow, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
Initial impacts of the COVID-19 pandemic on sexual and reproductive health service use and unmet need in Britain: findings from a quasi-representative survey (Natsal-COVID)
Authors: Emily Dema, Jo Gibbs, Soazig Clifton, Andrew J Copas, Clare Tanton, Julie Riddell, Raquel Bosó Pérez, David Reid, Chris Bonell, Magnus Unemo, Catherine H Mercer, Kirstin R Mitchell, Pam Sonnenberg, Nigel Field
Journal: The Lancet Public Health (2022)

The COVID-19 pandemic has affected sexual and reproductive health (SRH) service use and unmet need, but the impact is unknown. We aimed to determine the proportion of participants reporting sexual risk behaviours, SRH service use and unmet need, and to assess remote sexually transmitted infection (STI) testing service use after the first national lockdown in Britain.
The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer.
Authors: Kangho Suh, Josh John Carlson, Fang Xia, Todd E. Williamson, Sean D. Sullivan
Journal: Journal of Clinical Oncology (2022)

41 Background: Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the US, driven primarily by those with metastatic disease. For patients with metastatic disease who have progressed through available first- and second-line options, the standard of care systemic therapies are regorafenib or trifluridine/tipiracil. Larotrectinib is approved for patients with TRK fusion advanced solid tumors including metastatic CRC. Our objective was to compare expected life-years (LYs) and quality-adjusted life-years (QALYs) for metastatic CRC patients eligible to receive larotrectinib, regorafenib or trifluridine/tipiracil. Methods: We developed a partitioned survival model to project long-term comparative effectiveness of larotrectinib vs. regorafenib or trifluridine/tipiracil. Larotrectinib survival data, assessed by independent review committee, were derived from a July 2020 analysis of 8 adult (≥18 years of age) metastatic TRK fusion CRC patients from the larotrectinib clinical trials program (NCT02122913, NCT02637687, and NCT02576431). Survival inputs for regorafenib and trifluridine/tipiracil were derived from the CORRECT trial (NCT01103323) and the RECOURSE trial (NCT01607957), respectively. Progression-free (PFS) and overall survival (OS) for larotrectinib, regorafenib, and trifluridine/tipiracil were estimated using survival distributions (Exponential, Weibull, Log-logistic, and Log-normal) fit to the available data. Exponential fits were used based on goodness-of-fit and clinical plausibility. QALYs were estimated by adjusting the time spent in the pre-progression and post-progression health states by health state utilities derived from publicly available literature. In accordance with standard practice in health economics and outcomes research on future health benefits, a constant discount rate of 3% was applied to the LYs and QALYs. Model uncertainty was evaluated using one-way sensitivity analysis and probabilistic sensitivity analysis with 10,000 simulations. Results: Larotrectinib resulted in 2.11 LYs and 1.60 QALYs compared to 0.83 LYs and 0.59 QALYs for regorafenib and 0.85 LYs and 0.60 QALYs for trifluridine/tipiracil. These estimates yielded additional gains for larotrectinib of 1.28 LYs (1.01 QALYs) and 1.26 LYs (0.99 QALYs) against regorafenib and trifluridine/tipiracil, respectively. Conclusions: In metastatic CRC, larotrectinib may produce substantial life expectancy and quality-adjusted life-year gains compared to regorafenib or trifluridine/tipiracil. Additional data with longer follow-up times will further inform this comparison.
Increased Uptake of 18F-PSMA-1007 in Corpus Luteum Demonstrated by PET/CT
Authors: Astrid Geysen, Karolien Goffin, Donatienne Van Weehaeghe, Koen Van Laere, Christophe M. Deroose
Journal: Clinical Nuclear Medicine (2022)

Two women were referred for an 18F-PSMA-1007 PET/CT in follow-up of an adenoid cystic tumor of the subglottic region and the bronchus, respectively. Only limited tracer uptake was seen in the region of local recurrence and in the region of known metastases. Unexpectedly, an incidental finding consisting of a high tracer uptake at a corpus luteum in the ovary was found in both women.
Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies
Authors: Guanyu Chen, Weirong Kang, Wanqiong Li, Shaomeng Chen, Yanfeng Gao
Journal: Theranostics (2022)

The past few years has witnessed a booming market of protein and peptide drugs, owing to their superior efficiency and biocompatibility.Parenteral route is the most commonly employed method for protein and peptide drugs administration.However, short plasma half-life protein and peptide drugs requires repetitive injections and results in poor patient compliance.Oral delivery is a promising alternative but hindered by harsh gastrointestinal environment and defensive intestinal epithelial barriers.Therefore, designing suitable oral delivery systems for peptide and protein drugs has been a persistent challenge.This review summarizes the main challenges for oral protein and peptide drugs delivery and highlights the advanced formulation strategies to improve their oral bioavailability.More importantly, major intestinal cell types and available targeting receptors are introduced along with the potential strategies to target these cell types.We also described the multifunctional biomaterials which can be used to prepare oral carrier systems as well as to modulate the mucosal immune response.Understanding the emerging delivery strategies and challenges for protein and peptide drugs will surely inspire the production of promising oral delivery systems that serves therapeutic needs in clinical settings.
Table of Contents
Authors: Andrew Creadore, Jacqueline Watchmaker, Mayra Maymone, Leontios Pappas, Christina Lam, Neelam Vashi, Jane Grant-Kels, Brett Sloan, Jonathan Kantor, Dirk Elston, Warren Heymann, Carter Haag, Lindsay Bacik, Emile Latour, Daniel Morse, Nicole Fett, Alex Ortega-Loayza, Amy Paller, Regina Fo¨lster-Holst, Suephy Chen, Thomas Diepgen, Craig Elmets, David Margolis, Brad Pollock, Shari Wright, Allireza Alloo, Andrew Strunk, Amit Garg, Maria Ibanez, Kyle Rismiller, Thomas Knackstedt, Yiping Ge, Ying Yang, Lifang Guo, Mengli Zhang, Qiuju Wu, Rong Zeng, Huizhen Rong, Gaorong Jia, Hualing Shi, Jing Fang, Tong Lin, Amrita Goyal, Daniel O'leary, Kavita Goyal, Nathan Rubin, Kimberly Bohjanen, Maria Hordinsky, Steven Chen, Georgios Pongas, Lyn Duncan, Aleksandr Lazaryan, Mirjam Schaap, Marieke Van Winden, Marieke Seyger, Elke De Jong, Satish Lubeek, Amy Xu, Amrita Balgobind, Shamir Geller, Emily Lebowitz, Melissa Pulitzer, Steven Horwitz, Alison Moskowitz, Steve Dusza, Patricia Drph, Rebecca Levy, Lauren Briggs, Earl Silverman, Elena Pope, Irene Lara-Corrales, Ellie Rashidghamat, Tendai Kadiyirire, Salma Ayis, Gabriela Petrof, Lu Liu, Venu Pullabhatla, Chrysanthi Ainali, Alyson Guy, Sophia Aristodemou, James Mcmillan, Linda Ozoemena, John Mee, Rashida Pramanik, Alka Saxena, Rosamund Nuamah, Emanuele De Rinaldis, Sonia Serrano, Clarisse Maurin, Magdalena Martinez-Queipo, Su Lwin, Dusko Ilic, Anna Martinez, Francesco Dazzi, Ineke Slaper-Cortenbach, Sabrina Zeddies, Marcel Van Den Broek, Alexandros Onoufriadis, Jemima Mellerio, John Mcgrath, Agne `s Galezowski, Julie Delyon, Laurence Le Cleach, Sarah Gue´gan, Emilie Ducroux, Alexandre Alanio, Diane Lastennet, Philippe Moguelet, Ali Dadban, Marie The´re`se Leccia, Le Pelletier, Camille France, Ce´leste Lebbe´, Niki Vora, Karen Connolly, Stephen Dusza, Anthony Drph, Kishwer Rossi, Erica Nehal, Kelly Sinx, Patty Nelemans, Nicole Kelleners-Smeets, Veronique Winnepenninckx, Aimee Arits, Klara Mosterd
Journal: Journal of the American Academy of Dermatology (2020)
Toward Artificial Intelligence–Driven Pathology Assessment for Hematologic Malignancies
Authors: Olivier Elemento
Journal: Blood Cancer Discovery (2021)

Abstract Summary: In this issue of Blood Cancer Discovery, Brück and colleagues applied unsupervised and supervised machine learning to bone marrow histopathology images from patients with myelodysplastic syndrome (MDS). Their study provides new insights into the pathobiology of MDS and paves the way for increased use of artificial intelligence for the assessment and diagnosis of hematologic malignancies. See related article by Brück et al., p. 238.